Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/II, Open Label, Multicenter Study of Rapcabtagene Autoleucel in Adult Patients With CLL/SLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL

NCT03960840 is registered in ClinicalTrials.gov with Novartis Pharmaceuticals as lead sponsor.

NCT NCT03960840
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03960840 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/II, Open Label, Multicenter Study of Rapcabtagene Autoleucel in Adult Patients With CLL/SLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL
Lead sponsor
Novartis Pharmaceuticals
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
June 26, 2019
Completion date
May 31, 2028
Enrollment
217 (actual)
Sites
37

Conditions

As the registry lists them; a condition with its own page is linked.

acute lymphoblastic leukemia, chronic lymphocytic leukemia, diffuse large b-cell lymphoma, large b-cell lymphoma, small lymphocytic lymphoma